Biotech Firms Mull Acquisition Offers Amid Shaky IPO Climate

Biotech Firms Mull Acquisition Offers Amid Shaky IPO Climate

August 9, 2024, Law360

Megan Gates’ commentary was included in a Law360 article covering how biotechnology firms are exploring acquisition offers from larger pharmaceutical companies as a more certain exit strategy in an uncertain initial public offering (IPO) environment. Megan observed that “companies I work with are definitely considering M&A opportunities, probably more so than they might otherwise have been, given the lackluster IPO path.”